Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: GlobalData
$250.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Nattopharma ASA Announces Result of Vitamin K2 Plus Vitamin D Study


Wednesday, 2 Oct 2013 07:13am EDT 

Nattopharma ASA announced that in just-completed randomized human clinical trail in patients with chronic renal disease, the cardiovascular effects of oral administration of vitamin K2 (MenaQ7 brand) plus vitamin D or vitamin D alone were evaluated. In this six-month study, the progression of coronary artery calcification index (CAC) and common carotid intima media thickness (CCA-IMT) - both markers of calcium deposits in arteries detected with computerized tomography - showed a slower progression of the calcification in the vitamin K2/vitamin D group than detected in the vitamin D-alone group of patients. It was stated this is the first clinical evaluation showing that progression of arterial calcification can be prevented with supplemental vitamin K2. 

Company Quote

17.8
-1.0 -5.32%
25 Jul 2014